Pfizer agrees to license 30 products to Russian pharma company

Print 19 July 2016
Life Sciences IP Review

US drugs company Pfizer has entered into a manufacturing and licensing agreement with Russian pharmaceutical company NovaMedica.

Pfizer has proposed to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region.

The technology for production of more than 30 medicinal products from Pfizer’s portfolio will also be licensed to the Russian company.

In a press release, Pfizer and NovaMedica announced that the design, development and construction of the manufacturing plant are scheduled to begin in 2016, with the start of medicine production planned for 2020.

Petra Weil, regional president of Europe from Pfizer, said: “We contribute broadly to the modernisation of the Russian pharmaceutical industry, education in medicine and high-quality manufacturing and bringing innovation in the field of medicine.”

Brian Dovey, member of the board of directors of NovaMedica, said: “The strategic partnership with Pfizer provides a major boost toward NovaMedica’s goal of becoming a world-class leader in the fast-growing Russian pharmaceutical market.”‎

Source

Return